{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Philadelphia-Positive+Myeloid+Leukemia&page=6", "query": { "condition": "Philadelphia-Positive Myeloid Leukemia", "page": 6 }, "page_size": 10 }, "pagination": { "page": 6, "page_size": 10, "total_count": 931, "total_pages": 94, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Philadelphia-Positive+Myeloid+Leukemia&page=7&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Philadelphia-Positive+Myeloid+Leukemia&page=5&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-07T14:47:45.129Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00397813", "title": "Fludarabine Phosphate and Total Body Irradiation Followed by a Donor Peripheral Stem Cell Transplant in Treating Patients With Myelodysplastic Syndromes or Myeloproliferative Disorders", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative", "Chronic Myelomonocytic Leukemia", "de Novo Myelodysplastic Syndrome", "Essential Thrombocythemia", "Myeloproliferative Neoplasm", "Paroxysmal Nocturnal Hemoglobinuria", "Polycythemia Vera", "Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase", "Primary Myelofibrosis", "Refractory Anemia", "Refractory Anemia With Excess Blasts", "Refractory Anemia With Ring Sideroblasts", "Refractory Cytopenia With Multilineage Dysplasia", "Refractory Cytopenia With Multilineage Dysplasia and Ring Sideroblasts" ], "interventions": [ { "name": "Cyclosporine", "type": "DRUG" }, { "name": "Fludarabine Phosphate", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Mycophenolate Mofetil", "type": "DRUG" }, { "name": "Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation", "type": "PROCEDURE" }, { "name": "Peripheral Blood Stem Cell Transplantation", "type": "PROCEDURE" }, { "name": "Total-Body Irradiation", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "OTHER", "PROCEDURE", "RADIATION" ], "sponsor": "Fred Hutchinson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "50 Years to 75 Years" }, "enrollment_count": 77, "start_date": "2006-01", "completion_date": "2018-03", "has_results": true, "last_update_posted_date": "2020-01-31", "last_synced_at": "2026-10-07T14:47:45.129Z", "location_count": 3, "location_summary": "Salt Lake City, Utah • Seattle, Washington", "locations": [ { "city": "Salt Lake City", "state": "Utah" }, { "city": "Seattle", "state": "Washington" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT00397813" }, { "nct_id": "NCT00354172", "title": "Donor Umbilical Cord Blood Natural Killer Cells, Aldesleukin and Umbilical Cord Blood Transplant in Patients With Refractory Hematologic Cancers.", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Leukemia", "Myelodysplastic Syndromes" ], "interventions": [ { "name": "aldesleukin", "type": "BIOLOGICAL" }, { "name": "filgrastim", "type": "BIOLOGICAL" }, { "name": "natural killer cell (NK) therapy", "type": "BIOLOGICAL" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "cyclosporine", "type": "DRUG" }, { "name": "fludarabine phosphate", "type": "DRUG" }, { "name": "methylprednisolone", "type": "DRUG" }, { "name": "mycophenolate mofetil", "type": "DRUG" }, { "name": "Umbilical Cord Blood Transplantation (UCBT)", "type": "PROCEDURE" }, { "name": "Total body irradiation (TBI)", "type": "RADIATION" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE", "RADIATION" ], "sponsor": "Masonic Cancer Center, University of Minnesota", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "45 Years", "sex": "ALL", "summary": "Up to 45 Years" }, "enrollment_count": 16, "start_date": "2006-02", "completion_date": "2008-08", "has_results": true, "last_update_posted_date": "2017-12-28", "last_synced_at": "2026-10-07T14:47:45.129Z", "location_count": 1, "location_summary": "Minneapolis, Minnesota", "locations": [ { "city": "Minneapolis", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT00354172" }, { "nct_id": "NCT00038675", "title": "Therapy of HES, PV, Atypical Chronic Myelocytic Leukemia (CML) or Chronic Myelomonocytic Leukemia (CMML), and Mastocytosis With Imatinib Mesylate", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Chronic Myelomonocytic Leukemia", "Chronic Myeloid Leukemia", "Polycythemia Vera", "Hypereosinophilic Syndrome", "Mastocytosis" ], "interventions": [ { "name": "Imatinib Mesylate (Gleevec)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 125, "start_date": "2001-06", "completion_date": "2013-11", "has_results": true, "last_update_posted_date": "2022-01-04", "last_synced_at": "2026-10-07T14:47:45.129Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00038675" }, { "nct_id": "NCT00975975", "title": "Basiliximab #2: In-Vivo Activated T-Cell Depletion to Prevent Graft-Versus_Host Disease (GVHD) After Nonmyeloablative Allotransplantation for the Treatment of Blood Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acute Myelogenous Leukemia", "Acute Lymphocytic Leukemia", "Chronic Myelogenous Leukemia", "Chronic Lymphocytic Leukemia", "Myelodysplasia", "Non-Hodgkin's Lymphoma", "Hodgkin's Disease", "Multiple Myeloma", "Myelofibrosis", "Anemia, Aplastic", "Hemoglobinuria, Paroxysmal" ], "interventions": [ { "name": "Basiliximab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Indiana University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 17, "start_date": "2009-09", "completion_date": "2013-11", "has_results": true, "last_update_posted_date": "2016-02-26", "last_synced_at": "2026-10-07T14:47:45.129Z", "location_count": 1, "location_summary": "Indianapolis, Indiana", "locations": [ { "city": "Indianapolis", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT00975975" }, { "nct_id": "NCT00084695", "title": "Umbilical Cord Blood for Stem Cell Transplantation in Treating Young Patients With Malignant or Nonmalignant Diseases", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Childhood Langerhans Cell Histiocytosis", "Fanconi Anemia", "Leukemia", "Lymphoma", "Myelodysplastic Syndromes", "Neuroblastoma", "Sarcoma", "Unspecified Childhood Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "anti-thymocyte globulin", "type": "BIOLOGICAL" }, { "name": "busulfan", "type": "DRUG" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "fludarabine phosphate", "type": "DRUG" }, { "name": "melphalan", "type": "DRUG" }, { "name": "methylprednisolone", "type": "DRUG" }, { "name": "radiation therapy", "type": "RADIATION" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "RADIATION" ], "sponsor": "Milton S. Hershey Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "21 Years", "sex": "ALL", "summary": "Up to 21 Years" }, "enrollment_count": 25, "start_date": "2003-09", "completion_date": null, "has_results": false, "last_update_posted_date": "2014-01-10", "last_synced_at": "2026-10-07T14:47:45.129Z", "location_count": 1, "location_summary": "Hershey, Pennsylvania", "locations": [ { "city": "Hershey", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00084695" }, { "nct_id": "NCT00101231", "title": "Flavopiridol in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Chronic Myelogenous Leukemia", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Adult Acute Basophilic Leukemia", "Adult Acute Eosinophilic Leukemia", "Adult Acute Megakaryoblastic Leukemia (M7)", "Adult Acute Minimally Differentiated Myeloid Leukemia (M0)", "Adult Acute Monoblastic Leukemia (M5a)", "Adult Acute Monocytic Leukemia (M5b)", "Adult Acute Myeloblastic Leukemia With Maturation (M2)", "Adult Acute Myeloblastic Leukemia Without Maturation (M1)", "Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities", "Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)", "Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)", "Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)", "Adult Acute Myelomonocytic Leukemia (M4)", "Adult Erythroleukemia (M6a)", "Adult Pure Erythroid Leukemia (M6b)", "Blastic Phase Chronic Myelogenous Leukemia", "Recurrent Adult Acute Lymphoblastic Leukemia", "Recurrent Adult Acute Myeloid Leukemia", "Relapsing Chronic Myelogenous Leukemia" ], "interventions": [ { "name": "alvocidib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": null, "sex": "ALL", "summary": "1 Year and older" }, "enrollment_count": 88, "start_date": "2004-10", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-06-04", "last_synced_at": "2026-10-07T14:47:45.129Z", "location_count": 1, "location_summary": "Columbus, Ohio", "locations": [ { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT00101231" }, { "nct_id": "NCT00053001", "title": "Thalidomide and Epoetin Alfa in Treating Anemia in Patients With Myelodysplastic Syndrome", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Anemia", "Leukemia", "Myelodysplastic Syndromes", "Myelodysplastic/Myeloproliferative Neoplasms" ], "interventions": [ { "name": "epoetin alfa", "type": "BIOLOGICAL" }, { "name": "thalidomide", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Fallon Clinic", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "21 Years", "maximum_age": null, "sex": "ALL", "summary": "21 Years and older" }, "enrollment_count": null, "start_date": "2001-06", "completion_date": "2007-10", "has_results": false, "last_update_posted_date": "2013-06-26", "last_synced_at": "2026-10-07T14:47:45.129Z", "location_count": 2, "location_summary": "Worcester, Massachusetts", "locations": [ { "city": "Worcester", "state": "Massachusetts" }, { "city": "Worcester", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT00053001" }, { "nct_id": "NCT00077181", "title": "3-AP and High-Dose Cytarabine in Treating Patients With Advanced Hematologic Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Accelerated Phase Chronic Myelogenous Leukemia", "Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities", "Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)", "Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)", "Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)", "Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)", "Blastic Phase Chronic Myelogenous Leukemia", "Recurrent Adult Acute Lymphoblastic Leukemia", "Recurrent Adult Acute Myeloid Leukemia", "Relapsing Chronic Myelogenous Leukemia", "Secondary Acute Myeloid Leukemia" ], "interventions": [ { "name": "cytarabine", "type": "DRUG" }, { "name": "triapine", "type": "DRUG" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 48, "start_date": "2004-01", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-01-24", "last_synced_at": "2026-10-07T14:47:45.129Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00077181" }, { "nct_id": "NCT00580281", "title": "Effect of Imatinib on Bone Metabolism in Patients With Chronic Myelogenous Leukemia or Gastrointestinal Stromal Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Gastric Cancer", "Leukemia", "Chronic Myelogenous Leukemia" ], "interventions": [ { "name": "blood test, urine test, and bone density x-ray.", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 33, "start_date": "2006-11", "completion_date": "2013-10", "has_results": false, "last_update_posted_date": "2013-10-24", "last_synced_at": "2026-10-07T14:47:45.129Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00580281" }, { "nct_id": "NCT00827099", "title": "Umbilical Cord Blood (UCB) Transplant, Fludarabine, Melphalan, and Anti-thymocyte Globulin (ATG) in Treating Patients With Hematologic Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Myeloproliferative Disorders", "Leukemia", "Lymphoma", "Multiple Myeloma and Plasma Cell Neoplasm", "Myelodysplastic Syndromes" ], "interventions": [ { "name": "anti-thymocyte globulin", "type": "BIOLOGICAL" }, { "name": "fludarabine phosphate", "type": "DRUG" }, { "name": "Melphalan", "type": "DRUG" }, { "name": "mycophenolate mofetil", "type": "DRUG" }, { "name": "tacrolimus", "type": "DRUG" }, { "name": "umbilical cord blood transplantation", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE" ], "sponsor": "Northside Hospital, Inc.", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 5, "start_date": "2006-06", "completion_date": "2009-11", "has_results": true, "last_update_posted_date": "2012-03-23", "last_synced_at": "2026-10-07T14:47:45.129Z", "location_count": 1, "location_summary": "Atlanta, Georgia", "locations": [ { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT00827099" } ] }